Danavorexton (TAK-925) : an orexin receptor 2 agonist as a new 'arousal' agent
Copyright © 2023 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved..
A preclinical study in animals has further characterised a new 'arousal' agent. Danavorexton (TAK-925) is an agonist for orexin receptor 2 where it promotes recovery from inhalational and i.v. anaesthesia and opioid sedation. Although danavorexton reverses opioid sedation, it does not compromise analgesia. This could be a useful addition to the postoperative drug cupboard.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
British journal of anaesthesia - 132(2024), 3 vom: 12. Feb., Seite 466-468 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lambert, David G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics, Opioid |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bja.2023.12.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368369722 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368369722 | ||
| 003 | DE-627 | ||
| 005 | 20240214233359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bja.2023.12.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368369722 | ||
| 035 | |a (NLM)38346840 | ||
| 035 | |a (PII)S0007-0912(23)00705-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lambert, David G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Danavorexton (TAK-925) |b an orexin receptor 2 agonist as a new 'arousal' agent |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a A preclinical study in animals has further characterised a new 'arousal' agent. Danavorexton (TAK-925) is an agonist for orexin receptor 2 where it promotes recovery from inhalational and i.v. anaesthesia and opioid sedation. Although danavorexton reverses opioid sedation, it does not compromise analgesia. This could be a useful addition to the postoperative drug cupboard | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a arousal | |
| 650 | 4 | |a danavorexton | |
| 650 | 4 | |a opioid | |
| 650 | 4 | |a orexin | |
| 650 | 4 | |a orexin receptor-2 | |
| 650 | 4 | |a sedation | |
| 650 | 7 | |a Orexin Receptors |2 NLM | |
| 650 | 7 | |a Orexins |2 NLM | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a TAK-925 |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 700 | 1 | |a Hirota, Kazuyoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of anaesthesia |d 1946 |g 132(2024), 3 vom: 12. Feb., Seite 466-468 |w (DE-627)NLM000000310 |x 1471-6771 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2024 |g number:3 |g day:12 |g month:02 |g pages:466-468 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bja.2023.12.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2024 |e 3 |b 12 |c 02 |h 466-468 | ||